Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Assets (2016 - 2025)

Historic Assets for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $726.6 million.

  • Usana Health Sciences' Assets rose 823.51% to $726.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $726.6 million, marking a year-over-year increase of 823.51%. This contributed to the annual value of $748.2 million for FY2024, which is 1824.33% up from last year.
  • Latest data reveals that Usana Health Sciences reported Assets of $726.6 million as of Q3 2025, which was up 823.51% from $734.5 million recorded in Q2 2025.
  • In the past 5 years, Usana Health Sciences' Assets ranged from a high of $748.2 million in Q4 2024 and a low of $556.1 million during Q4 2022
  • Its 5-year average for Assets is $629.4 million, with a median of $604.1 million in 2023.
  • As far as peak fluctuations go, Usana Health Sciences' Assets soared by 2397.85% in 2021, and later tumbled by 985.31% in 2022.
  • Quarter analysis of 5 years shows Usana Health Sciences' Assets stood at $578.9 million in 2021, then grew by 3.04% to $596.5 million in 2022, then increased by 6.07% to $632.8 million in 2023, then grew by 18.24% to $748.2 million in 2024, then fell by 2.89% to $726.6 million in 2025.
  • Its last three reported values are $726.6 million in Q3 2025, $734.5 million for Q2 2025, and $746.6 million during Q1 2025.